Hearing News Watch

Featured image for “Amptify Appoints Chris Cardinal as Chief Executive Officer”
Dec. 27, 2022

Amptify Appoints Chris Cardinal as Chief Executive Officer

HHTM
ST. LOUIS, MISSOURI — Amptify has announced that Chris Cardinal, President and Chief Operating Officer of Amptify, has been appointed Chief Executive Officer, effective immediately, succeeding Nancy Tye-Murray, PhD. Dr. Tye-Murray remains in her position as Chair of the Board and assumes the position of Chief Scientific Officer. Cardinal joined Amptify as President and COO in early 2019 on the
Featured image for “Difficulty Hearing in Background Noise Among Older Adults May Be Result of too Many Brain Cells Firing at Once, Say Researchers”
Dec. 23, 2022

Difficulty Hearing in Background Noise Among Older Adults May Be Result of too Many Brain Cells Firing at Once, Say Researchers

HHTM
BALTIMORE, MARYLAND — Looking for answers about how the brain works amid age-related hearing loss, Johns Hopkins Medicine researchers say they found that old mice were less capable than young mice of “turning off” certain actively firing brain cells in the midst of ambient noise. The result, they say, creates a “fuzzy” sound stage that makes it difficult for the
Featured image for “With New $1M Grant, Bionics Institute’s Novel Hearing Diagnostic System, EarGenie, Moves Towards Commercialization”
Dec. 22, 2022

With New $1M Grant, Bionics Institute’s Novel Hearing Diagnostic System, EarGenie, Moves Towards Commercialization

HHTM
MELBOURNE, AUSTRALIA — The Bionics Institute’s development of a ground-breaking hearing test for babies, called EarGenie ®, is one of 16 projects to be funded by the latest National Health and Medical Research Council (NHMRC) Development Grant round in December 2022. The awarded grant budget of $1,176,999.50 (~$788K USD) is the second highest amount given to any research project in the latest
Featured image for “New Study Finds Wrist Worn Device Provides Clinically Significant Reduction in Tinnitus Symptoms”
Dec. 21, 2022

New Study Finds Wrist Worn Device Provides Clinically Significant Reduction in Tinnitus Symptoms

HHTM
PALO ALTO, CALIFORNIA — Neosensory, a technology company designing breakthrough solutions for hearing loss, has published new results in their recent scientific study of Duo, their therapeutic intervention for tinnitus. The group of participants who used Neosensory’s Duo solution daily for eight weeks reported clinically significant reduction in their tinnitus severity. The paper is available online: Bimodal stimulation for the
Featured image for “Starkey’s Brandon Sawalich Wins Gold Stevie Award for Executive of the Year”
Dec. 20, 2022

Starkey’s Brandon Sawalich Wins Gold Stevie Award for Executive of the Year

HHTM
EDEN PRAIRIE, MINNESOTA – Starkey President and CEO Brandon Sawalich has been named Executive of the Year in the manufacturing category of the International Business Awards. This global recognition earned him a Gold Stevie Award, which is one of the world’s premier business accolades.  “I would like to thank the entire team for making this recognition possible. Our dedicated team works tirelessly to outdo
Featured image for “Otonomy Announces Plan to Liquidate Company Following Number of Ear Drug Failures”
Dec. 20, 2022

Otonomy Announces Plan to Liquidate Company Following Number of Ear Drug Failures

HHTM
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (Nasdaq: OTIC) has announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented
Featured image for “3M Seeks Appeals Court for Stay in Earplugs Case; Cites ‘Errors’ by Bankruptcy Judge”
Dec. 18, 2022

3M Seeks Appeals Court for Stay in Earplugs Case; Cites ‘Errors’ by Bankruptcy Judge

HHTM
(Reuters) 3M Co told a federal appeals court this week that an Indiana federal bankruptcy judge could have — and should have — followed any one of at least three distinct lines of reasoning to conclude that mass tort litigation over allegedly defective 3M Co military earplugs must be paused during the Chapter 11 bankruptcy of 3M’s Aearo Technologies LLC
Featured image for “<strong>Starkey Owner and Chairman Bill Austin Wins Stevie Lifetime Achievement Award</strong> ”
Dec. 17, 2022

Starkey Owner and Chairman Bill Austin Wins Stevie Lifetime Achievement Award 

HHTM
EDEN PRAIRIE, MINNESOTA – Starkey Owner and Chairman, Bill Austin, received a Lifetime Achievement Award for his many contributions to the hearing industry. This global recognition, received in the 2022 International Business Awards, earned him one of the world’s premier business accolades – a Gold Stevie Award.  “Bill Austin’s passion for helping others has driven every Starkey business decision for more than 60 years,” said Starkey
Featured image for “Widex Appoints Hearing Industry Veteran Alan Raffauf as VP of Marketing”
Dec. 17, 2022

Widex Appoints Hearing Industry Veteran Alan Raffauf as VP of Marketing

HHTM
HAUPPAUGE, NEW YORK — Reaffirming its commitment to serve as the ally of the independent audiologist, Widex Inc. announced the appointment of industry veteran Alan Raffauf, M.A. to the position of Vice President of Marketing, reporting directly to Sheena Oliver, Chief Marketing Officer, U.S. “Alan is both an experienced B2B and B2C marketer and a professional audiologist. As such, he brings to Widex a
Featured image for “Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss”
Dec. 15, 2022

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

HHTM
LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the company’s second hearing restoration candidate for sensorineural hearing loss (SNHL). FX-345 is a combination of two small